C17 Stock Chart & Stats
€12.24
-€0.19(-1.61%)
At close: 4:00 PM EDT
€12.24
-€0.19(-1.61%)
Day’s Range― - ―
52-Week Range€5.49 - €21.70
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€706.34M
Enterprise Value€1.17B
Total Cash (Recent Filing)€215.23M
Total Debt (Recent Filing)€728.00K
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Oct 29, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding84,120,940
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)9.93
Price to Sales (P/S)0.00
P/FCF Ratio-18.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€26.33Price Target Upside115.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash RunwayThe strengthened cash position gives Corvus a substantial operating runway for advancing its clinical programs without an immediate financing requirement. This improves planning flexibility, supports continued investment through important readouts, and reduces near-term balance-sheet pressure despite ongoing cash consumption.
Atopic Dermatitis EfficacyThe Phase 1 atopic dermatitis results provide encouraging evidence that Soquelitinib may deliver meaningful clinical activity with a favorable observed safety profile. If replicated in larger studies, this signal could support development in a sizable indication and strengthen the program’s commercial potential.
Diversified Clinical PipelineDevelopment across multiple indications creates several potential paths for clinical validation rather than relying on a single disease program. Defined studies and milestones in PTCL, dermatology, and asthma broaden the opportunity set and could improve the probability that one successful program supports future growth.
Bears Say
No Revenue And Persistent LossesCorvus remains pre-commercial, so it has no product revenue to offset research, development, and corporate expenses. Persistent losses limit internal funding capacity and leave future financial performance dependent on successful clinical development, regulatory progress, and eventual commercialization.
Accelerating Cash BurnThe higher development spend and widening cash outflow increase the resources required to sustain Corvus’s pipeline. Even with an extended runway, continued escalation could bring forward the need for additional capital and may constrain program prioritization if clinical timelines lengthen.
Clinical Execution And Futility RiskThe lead Phase III program carries material execution uncertainty because predefined futility criteria could stop the study before final data. Enrollment pace, event rates, and shifting timelines can affect development costs and delay validation, weakening the pipeline’s ability to support future commercialization.
Corvus Pharmaceuticals News
C17 FAQ
What was Corvus Pharmaceuticals Inc’s price range in the past 12 months?
Corvus Pharmaceuticals Inc lowest stock price was €5.49 and its highest was €21.70 in the past 12 months.
What is Corvus Pharmaceuticals Inc’s market cap?
Corvus Pharmaceuticals Inc’s market cap is €706.34M.
When is Corvus Pharmaceuticals Inc’s upcoming earnings report date?
Corvus Pharmaceuticals Inc’s upcoming earnings report date is Oct 29, 2026 which is in 14 days.
How were Corvus Pharmaceuticals Inc’s earnings last quarter?
Corvus Pharmaceuticals Inc released its earnings results on Aug 06, 2026. The company reported -€0.17 earnings per share for the quarter, missing the consensus estimate of -€0.142 by -€0.028.
Is Corvus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Corvus Pharmaceuticals Inc’s price is currently Undervalued.
Does Corvus Pharmaceuticals Inc pay dividends?
Corvus Pharmaceuticals Inc does not currently pay dividends.
What is Corvus Pharmaceuticals Inc’s EPS estimate?
Corvus Pharmaceuticals Inc’s EPS estimate is -0.17.
How many shares outstanding does Corvus Pharmaceuticals Inc have?
Corvus Pharmaceuticals Inc has 84,120,940 shares outstanding.
What happened to Corvus Pharmaceuticals Inc’s price movement after its last earnings report?
Corvus Pharmaceuticals Inc reported an EPS of -€0.17 in its last earnings report, missing expectations of -€0.142. Following the earnings report the stock price went down -1.925%.
Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in DE:C17
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corvus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€26.33 (115.08% Upside)
€26.33 (115.08% Upside)
Blogger Sentiment
Bullish
DE:C17 Sentiment 63%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
33.23%
12-Months-Change
Fundamentals
Return on Equity
-36.15%
Trailing 12-Months
Asset Growth
167.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
C17 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive development picture driven by a strong cash position, promising Phase 1 atopic dermatitis efficacy and safety signals, multiple planned trials across indications, and defined near-term catalysts (Angel cohort data, SEERA-1 topline, PTCL interim). These positives are tempered by substantially higher R&D spend and widening net losses, increased stock-based compensation, and clinical/regulatory execution risks (including a futility analysis and reliance on partner timelines). On balance the clinical progress and cash runway meaningfully outweigh the financial and execution risks in the near term.View all DE:C17 earnings summariesC17 Stock 12 Month Forecast
Average Price Target
€26.33
▲(115.08% Upside)